

LETTER OF INTENT
Novel Biomarkers 2017

DEADLINE: Wednesday, 19 April, 2017

Applicants will be notified of Proposal invitations in June 2017

This Letter of Intent is an example only. Do not complete this paper application.
 Please submit the Letter of Intent online through the Institute's grant management system at
<https://weston.smartsimple.ca/welcome/neuroscience>

Application Number:

Principal Applicant:

Project Title:

Applicant Details

Team Members	Organizations	Primary Contact Information	Role in Project	Estimated Time Spent on Project
1. Salutation:	Primary Organization:	Address:	<input type="checkbox"/> Principal Applicant	%
First Name:	Position Title:	Phone:		
Last Name:	Other Affiliations/ Position Titles:	Email:	<input type="checkbox"/> Co-Applicant <input type="checkbox"/> Collaborator	
2. Salutation:	Primary Organization:	Address:	<input type="checkbox"/> Principal Applicant	%
First Name:	Position Title:	Phone:		
Last Name:	Other Affiliations/ Position Titles:	Email:	<input type="checkbox"/> Co-Applicant <input type="checkbox"/> Collaborator	

Note: Projects are not limited to two team members as laid out on this sample application form; projects may include as many team members as needed for the successful execution of the project.

Application Overview

1. Keywords to describe the proposed work:

The Institute defines neurodegenerative diseases of aging to include:

- Alzheimer's disease
- Dementia with Lewy bodies
- Frontotemporal dementia
- Multiple system atrophy
- Parkinson's disease
- Progressive supranuclear palsy
- Vascular contributions to the above diseases (not stroke-mediated vascular disease)
- Prodromes to the above diseases, including
 - Mild cognitive impairment as prodromal to Alzheimer's disease
 - REM sleep behaviour disorder as prodromal to Parkinson's disease

Proposed projects may relate to any disease(s) but must have impact on the diseases above and will be adjudicated based on their potential impact on these diseases.

The Institute defines translational research to be:

Applied research towards developing therapeutics for the prevention and/or treatment of human disease.

The Institute defines therapeutics to be:

A pharmacological approach (including small molecules, biologics, cell therapies and vaccines, including drug repositioning and repurposing), medical device, surgical intervention, or magnetic or electrical brain stimulation. Complementary approaches such as exercise, acupuncture, music, dietary and nutritional supplements are not considered therapeutics. Therapeutics can be for symptomatic relief, disease modification, or prevention.

The Institute defines tools to be:

Items that accelerate development of therapeutics, e.g., imaging techniques or reagents, biomarkers, and diagnostics.

Tools must have direct impact on accelerating the translational development of therapeutics for neurodegenerative diseases of aging. Any value the tools contribute to basic research will not be taken into consideration, including the identification of genes implicated in disease. Tools that will expand our knowledge of basic research can be important for the field, but the Institute will only value the tool for its immediate impact on translational research. This means, for example, that tools will not be valued for their ability to help identify new targets.

2. Research will have an impact in which neurodegenerative diseases of aging?

(Please select all that apply. There is no benefit to selecting more diseases than fewer diseases.)

- | | |
|--|--|
| <input type="checkbox"/> Alzheimer's disease | <input type="checkbox"/> Progressive supranuclear palsy |
| <input type="checkbox"/> Dementia with Lewy bodies | <input type="checkbox"/> Vascular contributions to the listed diseases |
| <input type="checkbox"/> Frontotemporal dementia | <input type="checkbox"/> Prodromes to the listed diseases (please also check the disease(s) to which your condition is a prodrome) |
| <input type="checkbox"/> Multiple system atrophy | |
| <input type="checkbox"/> Parkinson's disease | |

3. Relevance of proposed work to the Institute's mandate: using the Institute's definitions (above), explain how the biomarker being developed in this project will have immediate impact on accelerating translational research for neurodegenerative diseases of aging *(maximum 200 words.)*

4. Have you applied to other funding agencies with the same proposed work? *(This information will not be used to assess the application.)*

- Yes *Please specify:*
 No

5. Is this your first time applying for a grant from the Institute?

(This information will not be used to assess the application.)

- Yes
 No

6. Is this your first application for a research grant specifically in the area of neurodegenerative diseases of aging?

(This information will not be used to assess the application.)

- Yes
 No

The scientific review committee for this program does not include UK or Ireland-based researchers. Please list the full names of any reviewers located outside of the UK or Ireland who are competitive with you and therefore should not review your application. Please do not exclude reviewers for other reasons as we are unable to honour those requests. Type "None" if you have no reviewer exclusion. *(This information will not be used to assess the application.)*

Project Information

1. Central hypothesis, goals and specific aims: *(maximum 200 words.)*

2. Background and significance: Why is it important that the proposed work be carried out? Evaluate existing knowledge and identify the gaps that this project is intended to fill. Describe pilot data to justify that the biomarker is ready for testing in clinical samples/data or patients, and upload the data separately. *(maximum 200 words.)*

3. Novelty of the biomarker: Justify why this biomarker would be considered novel for the disease of interest. *(maximum 200 words.)*

4. Experimental approach: Outline how the proposed work will be carried out and interpreted, including clear go/no-go criteria. Explain the source of the samples/data or patients; if new samples/data, or patients are being used, please justify why existing ones are not being used. Include power calculations. *(maximum 800 words.)*

5. How will a successful outcome accelerate the development of therapeutics for neurodegenerative diseases of aging? *(maximum 200 words.)*

List of publications cited in the application and other publications directly relevant to the proposed work: Please include full citations with a complete author list and PMID numbers.

Preliminary Data: *Pilot data to support the proposed work should be uploaded as a PDF of maximum 1 page.*